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SIVmac251 and its closely related derivatives SIVmac239 and SIVmac239/17E vary greatly in their susceptibility to neutraliza-
tion with homologous and heterologous antisera. Whereas SIVmac251 induces homologous neutralizing antibodies, the
antibodies induced by SIVmac239 rarely neutralize infectivity of this virus in lymphocyte cultures. In contrast, SIVmac239/17E
is remarkably susceptible to neutralization with homologous and heterologous antisera induced by other strains of SIVmac .
In this study, we studied the molecular basis for the neutralization of SIVmac239/17E. Using chimeric viruses in which
different regions of the env gene of both SIVmac239 and SIVmac239/17E were inserted into a background of either of the
parental genomes, we showed that the newly acquired neutralization properties of SIVmac239/17E were attributable to amino
acid substitutions between the V2 and V4 regions of gp120. Site-directed mutagenesis of the env gene in this region showed
that the arginine substitutions at positions 334 and/or 340 within the ‘‘V3’’ domain were fundamental to virus neutralization
but other substitutions in the V2–V4 region added to the ease of its neutralization since it became neutralizable with much
higher dilutions of serum. The molecular determinants for neutralization of this virus are distinct from those reported as
responsible for neutralization of SIVmac251 and both are distinct from SIVmac239. q 1996 Academic Press, Inc.
INTRODUCTION antibodies. A second problem is that the viral epitopes
responsible for eliciting neutralizing antibodies have not
Anti-lentiviral neutralizing antibodies generated during yet been defined. A linear epitope encoded by the V3
infection with these viruses are not curative and have domain of the gp120, once thought to be the principal
little apparent effect on the outcome of infection or dis- neutralization domain of the virus, has given way to
ease (Clements et al., 1988). However, such antibodies newer findings that conformational epitopes outside of
still hold a promise that if administered passively or in- the V3 domain also have a major impact on neutralization
duced prior to exposure to infectious virus, they could (Gorny et al., 1994; Hwang et al., 1992; Javaherian et al.,
either prevent infection or retard the rate of replication 1989; Kliks et al., 1993; Milich et al., 1993; Moore et al.,
and dissemination of the virus. Human immunodeficiency 1995; Wrin et al., 1995). These epitopes are not specific
virus type 1 (HIV-1) has major tropisms for CD4/ T-cells for all strains of the virus and they remain undefined.
and cells of macrophage lineage (Chesebro et al., 1992; We have used the SIVmac system (Chalifoux et al., 1987;Cordonnier et al., 1989; Cheng-Mayer et al., 1991; Takeu- Daniel et al., 1985; Kestler et al., 1990; Letvin et al., 1990)
chi et al., 1991; Westervelt et al., 1992). However, since to examine the specificities of neutralization of these
the profound immunosuppression caused by this virus viruses. We utilized SIVmac251 and two closely relatedis associated with elimination of CD4/ T-cells, efficacy strains of virus, SIVmac239 and SIVmac239/17E (Andersonof neutralizing antibodies against the virus is usually as- et al., 1993; Kestler et al., 1988; Naidu et al., 1988). Similar
sessed in CD4/ T-cell lines or in cultures of human pe- to different strains of HIV-1, these three viruses replicate
ripheral blood mononuclear cells (Golding et al., 1994). productively in macaque CD4/ T-cells, but vary greatly in
A major problem confronting selection of a neutralizing their efficiency of replication in macaque macrophages,
antibody-inducing vaccine against this virus is that anti- SIVmac251 and SIVmac239/17E being much more macro-bodies that neutralize laboratory strains of virus do not phage-tropic than virus SIVmac239. Earlier comparativenecessarily neutralize patient isolates of the virus (Gorny studies on neutralization of SIVmac251 had shown thatet al., 1994; Moore et al., 1995; Sattentau and Moore, although a synthetic peptide corresponding to the V3
1995; Wrin et al., 1995). This raises the issue of need domain of a laboratory strain of HIV-1 caused neutraliza-
for a vaccine that induces broadly effective neutralizing tion of this virus, antibodies prepared against the struc-
tural homologue of V3 from SIVmac251 did not neutralize
infectivity of the latter virus, suggesting fundamental dif-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (913) 588-5599. ferences in neutralization of the two agents (Javaherian
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et al., 1989, 1992). Other studies on the neutralization of tion of both SIVmac239 and SIVmac239/17E (Stephens et
al., 1995).SIVmac251 suggest a role for conformational epitopes
in different regions of the virus envelope (Kent et al.,
Antibodies1992). Using SIVmac251 for background studies, we exam-
ined the molecular determinants for neutralization of Plasma collected from macaques previously infected
SIVmac239/17E, a virus that is easily neutralized when with SIVmac239 (macaques 1F, 197, 262), SIVmac239/17E
compared to neutralization-resistant SIVmac239. Our stud- (macaques M6, M7), or SIVmac251 (macaque 20B) were
ies indicate that amino acid substitutions in the ‘‘V3’’ re- used as a source of anti-SIVmac antibodies (Joag et al.,
gion of SIVmac239/17E defined the neutralization pheno- 1995; McEntee et al., 1992). Plasma samples were col-
type of the agent, but the neutralization process was lected at approximately 6 months following inoculation
amplified by other substitutions in the V2–V4 regions of with the SIVmac strains. All plasma samples were heated
the env gene of the virus. These results are similar to at 567 for 30 min prior to use.
the neutralization laboratory strains of HIV-1 and distinct
from determinants of neutralization of SIVmac251. Thus, Virus assay
each of the three strains of SIVmac used in the study
Replication of the viruses in this study was assessedshowed that despite their close phylogenetic relation-
by cytopathology and Western blot analyses. CEMx174ship, each virus had specific neutralization determinants.
cells transfected with each viral genome were exam-
ined daily for up to 2 weeks for the development of
MATERIALS AND METHODS syncytial cytopathology (CPE). Virus replication was
also assessed by examining virus protein synthesis by
Viruses and plasmids Western blot analyses. In this procedure, CEMx174
cells from transfections were examined for the pres-The plasmids p239SpE3* and p239SpSp5* containing
ence or absence of viral proteins. Specifically, cultures5* and 3* halves of the molecularly cloned SIVmac239
were harvested by centrifugation in a microfuge at 6000have been described previously (Regier and Desrosiers,
rpm for 5 min. The cell pellets were resuspended in 901990). The SIV sequences were excised from
ml of phosphate-buffered saline and 30 ml of 41 SDS –p239SpSp5* and p239SpE3* and used to construct an
PAGE sample reducing buffer. Samples were boiled forinfectious viral genome in the plasmid pBS (Stratagene).
5 min, chilled on ice, and briefly sonicated to shear theThe resulting plasmid was designated pBS239. The con-
DNA. Eight microliters (for 15-well gel) or 20 ml (forstruction of the SIVmac239/17E has been described pre-
10-well gel) of each sample was loaded onto SDS –viously and was obtained in plasmid pUC19 from Dr.
polyacrylamide gels (8.5% gel) and proteins were sepa-J. E. Clements at Johns Hopkins University (Anderson
rated by electrophoresis (Laemmli, 1970). The sepa-et al., 1993). Sequence analysis of the entire envelope
rated proteins were transferred electrophoretically fromglycoprotein gene of SIVmac239/17E in our lab revealed
the gels onto nitrocellulose membranes and blocked13 amino acid substitutions from the glycoprotein of
by incubation in 10% milk – Tris buffer overnight. TheSIVmac239. A schematic diagram denoting the amino acid
membranes were reacted overnight at room tempera-differences between the SIVmac239 and the SIVmac239/
ture with plasma from a monkey infected previously with17E gp160 proteins is shown in Fig. 2. Plasmids were
SIVmac239/17E and proteins visualized by reacting thealso constructed to contain SphI/XmnI fragments (nt 6445
membranes with alkaline phosphatase-labeled proteinto 8902) of the SIVmac239/17E or SIVmac239 genomes.
A and substrate (nitro BT and 5-bromo-4-chloro-3-indoylThese fragments, encoding most of the env gene and all
phosphate). In the gels shown, the CA protein (p27)of the amino acid differences were subcloned into the
was allowed to run off and hence only the glycoproteinSphI/SmaI sites of pGEM3Zf(0) and were designated
complex was detected using Western blot analysis. Inp17ESX or p239SX. The plasmid p7FLN1, containing the
other analyses in which the CA was not allowed to rungp120 sequence isolated from the lymph node of an ani-
off the gel, both the glycoprotein complex and the CAmal previously inoculated with SIVmac239, has been re-
protein were detected (data not shown).ported previously (Zhu et al., 1995).
Virus neutralization assays
Cells
To determine the virus neutralization titers of the vari-
ous plasmas against the viruses used in this study, 50The CEMx174 cell line used in this study is a human
T–B cell hybrid cell line described previously (Salter et ml of medium containing 10–100 tissue culture infectious
doses (TCID50) of each virus was mixed with twofoldal., 1985). CEMx174 cells were maintained in RPMI 1640
medium supplemented with 10 mM HEPES buffer, 1005 M dilutions of plasma (from 1:10 dilution to 1:20,480) in qua-
druplicate in a 96-well plate for 2 hr at 377, after which2-mercaptoethanol, 10 mg/ml gentamicin, and 10% fetal
bovine serum and are susceptible to cytopathic replica- 100 ml medium containing 1 1 104 CEMx174 cells (m.o.i.
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of 0.001–0.01) was added to each well. Cultures were of SIVmac239, SIVmac239/17E, or various chimeric viruses
in plasmid pBS using the DEAE-dextran transfectionobserved for development of CPE during a 7-day period.
Cell pellets were then harvested by centrifugation and method (Milman and Herzberg, 1981; Sompayrac and
Danna, 1981). Following transfection, cells were incu-used in Western blot analyses to confirm the results of
the neutralization assays. The titers were expressed as bated for 7 days at 377 at which time fresh medium and
fresh CEMx174 cells were added to the cultures. At 750% end points. We have also compared the results of
virus neutralization at both 7 and 14 days. Our results days posttransfection, the culture media were clarified
by centrifugation at 2000 rpm for 10 min and stored inindicate that no additional CPE was observed in negative
cultures and Western blot analyses of viral proteins from 1-ml aliqouts at 0807 as virus stocks. Virus stocks were
titrated in CEMx174 cells as described before (Joag etcell pellets were identical to the results from the 7-day
assays (data not shown). al., 1994). The cell pellets from transfections were frozen
at 0807 and used later for detection of virus proteins by
Construction of chimeric viruses with different Western blot analysis.
regions of the SIVmac239 and SIVmac239/17E env
genes Site-directed mutagenesis of the viral envelope
glycoproteinA schematic diagram of chimeric viruses constructed
with different regions of the env gene from SIVmac239 and Site directed mutagenesis of the env gene was per-
SIVmac239/17E is shown in Fig. 2. Chimeric genomes GI formed using the polymerase chain reaction (PCR) tech-
and GH were constructed with reciprocal SphI/PstI frag-
nique (Saiki et al., 1985, 1988) and the conditions de-
ments, GI and GJ with the ClaI/NheI fragments, and GK
scribed previously (Zhu et al., 1995). Two rounds of PCR
and GL with the PstI/ClaI fragments between the
amplification were performed to obtain the desired muta-
SIVmac239 and the SIVmac239/17E env genes in p239SX tions. The first-round PCR generated a small fragment of
and p17ESX, respectively (see Fig. 2). The constructed
DNA which contained the desired mutation(s) and a MroI
chimeric env genes were released from p239SX or
restriction endonuclease site. The oligonucleotides used
p17ESX subclones by digestion with SphI and NheI and
in the first round were ES56, 5*-CAC TTC TGT TAT CCA
cloned into these sites in the pBS239 vector.
AGA GTC TTG TGA-3* (coding strand, from nt 7239 to
For construction of chimeric genomes CE and ZS, plas-
7265); ES62, 5*-CT AAC AAT GAA ATG TAG AAG ACC
mid p7FLN1 was utilized. This plasmid contains a gp120
AGG-3* (coding strand, from nt 7522 to 7547); and ES18,
sequence isolated from the lymph node of macaque 7F
5*-GGT AAC TTC CGG ATC TCC TCC TCC AGG-3* (non-
(Zhu et al., 1995). The predicted amino acid between the
coding strand, from nt 7744 to 7770). The introduced
PstI and MroI sites was identical to SIVmac239 except for nucleotide substitutions are underlined. The positions of
two amino acid substitutions, an isoleucine at position
the oligonucleotides used were based on the sequence
309 and an arginine at position 382 (see Fig. 5). For
of SIVmac239 (Regier and Desrosiers, 1990). The desiredgenome CE, this plasmid was digested with PstI and
fragment was purified by agarose gel electrophoresis
MroI (nucleotide 7169 to 7757 of the viral genome) and
and used with oligonucleotide ES17 (5*-ACC ATG ACA
the 588-bp fragment isolated on an agarose gel following
GGG TTA AAA AGA GAC AAG-3*, coding strand, from
electrophoresis. The isolated DNA fragment was then
nt 7114 to 7140) in the second round of PCR with the
subcloned into the PstI and MroI sites of the p17ESX.
appropriate template to generate a fragment which con-
For construction of virus ZS, p7FLN1 was digested with
tained the desired mutations with PstI and MroI restric-
ApaLI and MroI to release a 450-bp fragment encom-
tion endonuclease sites. The second-round PCR prod-
passing the ‘‘V3’’ domain and containing the methionine
ucts were directly digested with PstI and MroI and the
to isoleucine and glycine to arginine substitutions at po-
588-bp fragment was cloned into the PstI and MroI sites
sitions 309 and 382, respectively. Next plasmid p17ESX
of the p17ESX vector to construct the mutant subclones.
was digested with MroI and partially digested with ApaLI
The mutant env genes were released by digestion with
(which has multiple sites in the vector) and ligated with
SphI and NheI and used to replace the env gene of
the 450-bp fragment isolated above. Intact viral genomes
SIVmac239 in the pBS239 vector. The env genes of allwere constructed by digestion of these recombinant env
mutants were subjected to DNA sequence analyses to
gene plasmids with SphI and NheI, isolation of the 2.3-
confirm that the desired mutations were achieved. Table
kb fragments, and cloning these fragments into pBS239.
1 lists the oligonucleotide primers and templates used
The construction of the chimeric viral genomes was con-
to generate chimeric viruses ZB, ZG, ZI, and ZP. For con-
firmed by sequence analyses.
struction of viral genome ZP, oligonucleotide primers
ES17 and ES18 were used in a PCR using plasmidTransfection and titration of virus stocks
p17ESX as the template. The 630-bp fragment was puri-
fied and then digested with PstI and MroI and clonedCEMx174 cells (3 1 106) were transfected with 5 mg
of each plasmid DNA containing the complete genomes into the p17ESX vector digested with the same restriction
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TABLE 1 and probably represents a neutralization subtype dif-
ferent from these two viruses. Further, the resultsOligonucleotide Primers and Templates Used in Site-Directed
showed the type specificity of some of these sera inMutagenesis of the SIV env
this assay system.
First-round PCR
Replication properties of chimeric viruses containing
Chimeric Oligonucleotide
different regions of the env gene of SIVmac239 andvirus primer Template Second-round PCR
SIVmac239/17E
ZB ES56, ES18 p17ESX Use first round PCR
When compared to SIVmac239, a total of 13 amino acidproduct and
substitutions were found in the env gene of SIVmac239/ES17 as primers.
ZG ES62, ES18 p17ESX 17E (Fig. 2). To determine which amino acid substitutions
ZI ES62, ES18 ZB Use ZB product in the SIVmac239/17E env gene contributed to its neutral-
from first round
ization properties, we first constructed six chimeric envand ES17
genes containing different groups of amino acid substitu-primers.
tions from SIVmac239/17E and SIVmac239. These con-ZP ES17, ES18 p17ESX None
structs are illustrated in Fig. 2. CEMx174 cells transfected
with either parental SIVmac239 or SIVmac239/17E devel-
oped CPE starting 2 days later and this progressed withenzymes. The mutant env gene was released by diges-
further incubation of cultures. Chimeric genomes con-tion with SphI and NheI and used to replace the env
taining different envelope gene substitutions fromgene of SIVmac239 in the pBS239 vector. Following their
SIVmac239/17E on the background of SIVmac239 causedconstruction and sequence analysis to confirm the de-
two patterns of CPE (Fig. 3). Cells transfected with chime-sired changes were accomplished, each viral genome
ric viral genomes GH, GJ, and GK developed progressivewas used to transfect CEMx174 cells to generate virus
CPE similar to that caused by SIVmac239, whereas cellsstocks for neutralization assays.
transfected with chimeric viral genomes GG, GI, and GL
developed only minimal CPE 2 days posttransfection (Fig.RESULTS
3) and this disappeared with continued incubation.
Antibodies in plasma samples from macaques There was a correlation between the progressive CPE,
infected with SIVmac239, SIVmac251, and SIVmac239/
17E identify SIVmac239/17E as a distinct neutralization
subtype
Six plasma samples from macaques previously inocu-
lated with SIVmac239, SIVmac239/17E, or SIVmac251 were
examined for neutralizing antibodies to these viruses in
the CEMx174 cell culture system. Titers were determined
by evaluation of cytopathicity with confirmation by West-
ern blot analyses (Fig. 1). The results shown in Table 2
demonstrate that all six plasma samples neutralized the FIG. 1. SIVmac239/17E is neutralized by a variety of plasma samples
infectivity of SIVmac239/17E at dilutions varying from 1:160 from SIVmac inoculated animals. 10–100 TCID50 of each virus was mixed
with a 1:10 dilution of each plasma in quadruplicate in a 96-well plateto 1:10,240. There was a correlation between the virus
and incubated at 377 for 2 hr. At the end of the 2-hr incubation period,used for inoculation of the animal and the corresponding
104 CEMx174 cells were added (m.o.i. 0.001–0.01) and cultures ob-neutralization titer against SIVmac239/17E. Macaques in- served for the appearance of syncytial cytopathology for 7 days. The
oculated with SIVmac239/17E (M6 and M7) had the high- presence or absence of CPE was noted. The cells from the neutraliza-
est neutralization titers (1:10,240), whereas the plasma tion tests were harvested and lysed, and proteins were separated using
SDS–PAGE and transferred onto nitrocellulose membranes for West-from 20B, inoculated with SIVmac251, had the lowest level
ern blot analyses using anti-SIV plasma as described under Materialsof neutralizing antibodies (1:160). None of these plasmas
and Methods. Lane 1 represents uninfected CEMx174 cells. Lanes 2–neutralized the infectivity of SIVmac239. Similarly, none of 7 represent SIVmac239 reacted with plasma from an uninfected ma-the five plasma samples originating from animals inocu- caque, 1F, 197, 262, M6, and M7, respectively. Lanes 8–13 represent
lated with SIVmac239 or SIVmac239/17E had neutralizing SIVmac239/17E reacted with plasmas from an uninfected macaque, 1F,
197, 262, M6, and M7, respectively. Hence, two parameters were usedantibodies against SIVmac251. In contrast, the plasma
to judge neutralization, the presence or absence of CPE which wassample originating from animal inoculated from
confirmed by the presence or absence of gp120 in Western blot analy-SIVmac251 (macaque 20B) had a neutralizing antibody titer ses. The CA protein (p27), also detected in these Western blot assays,
of 1:160 against both SIVmac251 and SIVmac239/17E. was allowed to run off the gel. In all cases, the appearance of CPE,
These results suggested that SIVmac239/17E was more indicating a lack of neutralization, and the presence of gp120 by West-
ern blot analyses were in agreement.‘‘easily neutralized’’ compared to SIVmac239 or SIVmac251
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TABLE 2
Plasma Neutralization Titers against SIVmac239, SIVmac239/17E, and SIVmac251
Macaque plasma
Virus used in
neutralization 1F 197 262 20B
test (239)a (239) (239) M6 (17E) M7 (17E) (251)
SIVmac239 1:10 1:10 1:10 1:10 1:10 1:10
SIVmac239/17E 1:1280 1:640 1:1280 1:10,240 1:10,240 1:160
SIVmac251 1:10 1:10 1:10 1:10 1:10 1:160
a Virus used to inoculate macaques is in parentheses.
expression of viral proteins, and production of infectious peared during the following 2 to 3 days. These results
suggested that these three viral genomes probably un-virus. CEMx174 cultures transfected with chimeric ge-
nomes GH, GJ, and GK and incubated for 7 days pro- derwent a single cycle of replication and that the virus
produced was incapable of spreading to adjacent cellsduced infectious virus with titers of 102.0, 104.1, and 102.1
TCID50 per milliliter, respectively, and developed progres- in culture due to a biologically inactive virus glycoprotein.
sive CPE. In contrast, cultures transfected with chimeric
viruses GG, GI, and GL and incubated for the same pe- Neutralization properties of the three replication-
riod of time produced undectable levels of gp120 and competent chimeric viruses
gag proteins as determined by Western blot analyses
(Fig. 4). These cultures developed a few small foci of None of the three cytopathic viruses (GH, GJ, GK) was
neutralized by the six plasma samples in Table 2. Virusesmultinucleated cells (fusion) by Day 2 but these disap-
FIG. 2. Schematic diagram of the envelope glycoprotein of SIVmac239, differences in the amino acid sequence between SIVmac239 and SIVmac239/
17E, and the restriction endonuclease sites used to construct chimeric viruses GG, GJ, GK, GH, GI, and GL. The location of the variable regions
V1, V2, ‘‘V3’’, V4, and V5 are shown in brackets. Listed on the right are the results denoting whether infectious virus was produced following
transfection into CEMx174 cells and virus neutralization in the presence of macaque M6 plasma. ND, not done.
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rationale used was to create different combinations of
these five amino acid substitutions from SIVmac239 and
SIVmac239/17E and to insert these into the glycoprotein
of each virus (Fig. 5). Six genomes were constructed
by site-directed mutagenesis. All contained the amino-
terminal portion of gp120 and the gp41 of SIVmac239/17E
but the region between V2 and V4 was altered to have
four (virus ZP), three (viruses ZB, ZG, and ZS), or two
(viruses CE and ZI) amino acids from SIVmac239/17E gly-
coprotein.
The first virus examined, ZG, was essentially a
SIVmac239/17E glycoprotein but with 239 amino acid sub-
stitutions at positions 309 and 382. This virus was neu-
tralized by a 1:2560 dilution of M6 plasma, indicating that
amino acid changes at positions 309 and 382 were
not required for defining the neutralization epitope of
SIVmac239/17E. By constructing virus ZB, we addressed
whether the lysine residue at position 217 was important
for SIVmac239/17E neutralization. This virus had the
SIVmac239 virus substitutions of a glutamine at position
217 and a glycine at position 382 but the isoleucine,
arginine, and arginine residues at amino acid positions
309, 334, and 340, respectively, from SIVmac239/17E (see
Fig. 5). This virus was replication competent but it was
neutralized at a 1:640 dilution of M6 plasma. Based on
the neutralization pattern of ZG and ZB, we concluded
that the lysine at position 217 and isoleucine at position
309 were not important for neutralization, whereas the
two arginine substitutions at positions 334 and 340 within
the ‘‘V3’’ region, common to both ZG and ZB, were im-
portant for defining the neutralization epitope of
SIVmac239/17E. We then examined the importance of the
glycine to arginine substitution at position 382 for neutral-
ization. Virus ZP was SIVmac239/17E without this substitu-
tion. It was also neutralized at a 1:2560 dilution of M6
plasma, indicating that this single substitution was notFIG. 3. Photomicrographs showing transient cytopathology observed
following transfection of CEMx174 cells with (A) pBS (control plasmid) important for neutralization of SIVmac239/17E.
or viral genomes (B) GH or (C) GL.
GH and GJ had SIVmac239 substitutions either in the
amino-terminal region of the gp120 or in the gp41 region,
respectively, but were still not neutralized by antibodies,
suggesting that these regions were not important for de-
fining the neutralization epitope of this virus. Since virus
GK contained the amino acid substitutions from the FIG. 4. Western blot analyses detect productive versus nonproduc-
amino terminus of gp120 and gp41 of SIVmac239/17E and tive infection following transfection of cells. CEMx174 cells were
transfected with chimeric virus genomes GG, GH, GI, GK, GJ, and GLfive amino acid substitutions from SIVmac239 in the region
as described under Materials and Methods and observed for the ap-between V2 and V4, failure of the virus to be neutralized
pearance of CPE over a 7-day period. Cultures transfected with GH,suggested that these five amino acid substitutions be-
GJ, and GK resulted in progressive CPE, whereas cultures transfected
tween the V2 and V4 regions were important for neutral- with chimeric genomes GG, GI, or GL had transient cytopathology (see
ization of SIVmac239/17E. Fig. 3 and text). To confirm the results of transfection of these virus
genomes into CEMx174 cells, cell pellets were harvested at 7 days
Amino acid substitutions in the ‘‘V3’’ region are after transfection and subjected to Western blot analyses to detect the
appearance or absence of viral proteins as described under Materialsessential for neutralization of SIVmac239/17E
and Methods. Lane 1 represents uninfected CEMx174 cells. Lanes 2–
We sought to determine which of these five amino 7, CEMx174 cells transfected with chimeric virus genomes GG, GH,
GI, GJ, GK, and GL, respectively.acid substitutions were important for neutralization. The
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FIG. 5. Schematic diagram of the envelope glycoprotein of SIVmac239, noting the differences in the amino acid sequence between SIVmac239 and
SIVmac239/17E, and location of restriction endonuclease sites used to construct chimeric viruses (CE and ZS) and mutant viruses constructed using
site-directed mutagenesis. For example, virus ZP was constructed such that it had amino acid substitutions from SIVmac239/17E at positions 217,
309, 334, and 340 and an amino acid substitution from SIVmac239 at position 382. Listed on the right are the results denoting whether infectious
virus was recovered following transfection in CEMx174 cells and the neutralization titer of each mutant against macaque M6 plasma (NT).
Having a strong indication that the two substitutions tutions outside the ‘‘V3’’ region had a further effect in
amplifying the susceptibility of this agent to neutraliza-in the ‘‘V3’’ were important for neutralization, we exam-
ined three new constructs, ZI, containing the two substi- tion. These conclusions are based on virus neutralization
titers that showed that a virus containing the two argininetutions in the ‘‘V3’’, and CE and ZS, both of which lacked
the ‘‘V3’’ changes but contained the other two and three substitutions in ‘‘V3’’ region of SIVmac239/17E was neutral-
ized at serum dilutions of 1:80, whereas three other vi-changes, respectively (CE: I and R at positions 309 and
382; and ZS: K, I, and R at positions 217, 309, and 382). ruses containing the two ‘‘V3’’ substitutions in addition to
Virus ZI was neutralized at a dilution of 1:80 but the other other substitutions in the V2 to V4 region increased the
two failed to be neutralized. These results illustrated susceptibility of neutralization to a dilution of 1:640 to
clearly that the two amino acid substitutions in the ‘‘V3’’ 1:2560 of the plasma. Our data with virus genomes GG,
were fundamental to neutralization. GI, and GL suggest that the amino acid substitutions from
V2–V4 probably interacted with the other substitutions at
either the amino terminus or the gp41 subunit to maintainDISCUSSION
the biological activity of the glycoprotein. These small
numbers of point mutations in the env gene illustrate theThe remarkable ease of neutralization of SIVmac239/
wide variations that are possible with respect to failure17E, in contrast to the equally impressive resistance of
of the virus to be neutralized or the high susceptibility ofparental and closely related SIVmac239 to neutralization
the virus to be neutralized with small amounts of anti-with homologous and heterologous macaque antibodies,
body. These results are very similar to the determinantsprovided an ideal framework to examine the molecular
responsible for the neutralization of laboratory strains ofdeterminants regulating susceptibility and resistance of
HIV-1.these viruses to neutralization. In this report, we show
Most of the studies on the antibody neutralization ofthat among the 13 amino acid substitutions in the env
SIVmac have been performed using a molecular clonegene that distinguish SIVmac239 from SIVmac239/17E, two
from macaque 251. A monoclonal antibody directed tosubstitutions in the ‘‘V3’’ region (proline to arginine substi-
the transmembrane protein was shown to have strain-tution at position 334 and/or a lysine to arginine substitu-
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